Despite over 1300 deaths in New Zealand each year from colorectal cancer, many treatment options offer poor survival benefits. Emerging therapies designed to target immune cells, a crucial development in tumour destruction, have proven ineffective against this silent killer.
However, ground-breaking research into gut bacteria and their by-products has demonstrated to improve patient responses to immunotherapies and increase immunity within this field.
This research is designed to identify which bacteria and bacterial products offer the most significant protection to patients to boost anti-tumour immunity and improve treatment outcomes to immunotherapy.
Funding: $97,500